Inactive Instrument

Company LYSOGENE

Equities

LYS

FR0013233475

Biotechnology & Medical Research

Business Summary

LYSOGENE is a biotechnology company specializing in the research and development of gene therapies for the treatment of rare neurodegenerative diseases.

The company now has 2 drug candidates in clinical development of which 1 in phase 2/3 (LYS-SAF302 for the treatment of Sanfilippo syndrome type A) and 1 in phase 1/2 (LYS-GM101 for the treatment of GM1 gangliosidosis).

Number of employees: 22

Managers

Managers TitleAgeSince
Chief Executive Officer 52 08-12-31
Director of Finance/CFO - 19-12-31
Chief Tech/Sci/R&D Officer - 22-01-31
Chief Tech/Sci/R&D Officer - 18-05-01
Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Director/Board Member 56 18-03-31
Director/Board Member 72 -
Chief Executive Officer 52 08-12-31
Director/Board Member - 19-09-25
Director/Board Member - -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 17,811,140 12,983,653 ( 72.90 %) 13,156 ( 0.0739 %) 72.90 %

Shareholders

NameEquities%Valuation
La Financière Desselligny SA
0.0411 %
7,352 0.0411 % 2 274 €

Company contact information

Lysogene SA

18-20, rue Jacques Dulud Neuilly-sur-Seine

92200, Paris

+33 1 41 43 03 90

http://www.lysogene.com
address LYSOGENE(LYS)